NCT04347005View on ClinicalTrials.gov

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 22, 2019

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

Cohort 1: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 2: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 3: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 4: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 5: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 6: AR882 Food Effect

Single dose of AR882 or matching placebo in a fed state

DRUG

Cohort 7: AR882 Solid Oral Formulation

Single dose of AR882 or matching placebo

DRUG

Cohort 8: AR882 in combination with allopurinol

Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol

DRUG

Cohort 9: AR882 in combination with febuxostat

Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat

Trial Locations (1)

3004

Nucleus Network Pty, Ltd., Melbourne

Sponsors
All Listed Sponsors
lead

Arthrosi Therapeutics

INDUSTRY

NCT04347005 - The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males | Biotech Hunter | Biotech Hunter